Skip to content
2000
Volume 2, Issue 2
  • ISSN: 1573-3963
  • E-ISSN: 1875-6336

Abstract

Systemic lupus erythematosus (SLE) is more severe in children than in adults, and often needs aggressive treatment. Classical (old ) therapies include mostly non-steroid anti-inflammatory drugs, hydroxychloroquine, corticosterois and cyclophosphamide. However, these two latter drugs can induce severe side effects. Recently, new drugs, especially Mycophenolate Mofetyl and anti-CD20 antibody, have been proved to be efficient and well tolerated in adult-onset SLE and may become mainstay therapeutic option for severe chidhood-onset lupus manifestations. Management of complications such as growth failure, osteoporosis, premature atherosclerosis and anti-phospholipid syndrome has also progressed within the last years. Beside these promising perspectives of treatment, psychological support, long-term follow-up and program of transition from the pediatric to the adult care unit remain essential.

Loading

Article metrics loading...

/content/journals/cpr/10.2174/157339606776894630
2006-05-01
2025-06-01
Loading full text...

Full text loading...

/content/journals/cpr/10.2174/157339606776894630
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test